TriVascular boosted by $60m financing round
This article was originally published in Clinica
Executive Summary
Endovascular graft firm TriVascular has secured $60m in funding, which it will use to commercialise its Ovation abdominal stent graft system in Europe. The company closed a series C financing round, which was led by new investor Pinnacle Ventures. Existing investors New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners also contributed. TriVascular (Santa Rosa, California) will use proceeds from the financing to launch Ovation in Europe, drive clinical research activity across three continents and fund next-generation product development. The Ovation system is designed to treat abdominal aortic aneurysm (AAAs), which affects nearly two million people in the US, according to TriVascular.